Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.
There is no licensed treatment for non-alcoholic fatty liver disease (NAFLD), a condition that increases risk of chronic liver disease, type 2 diabetes and cardiovascular disease. We tested whether 15-18 months treatment with docosahexaenoic acid (DHA) plus eicosapentaenoic acid (EPA) (Omacor/Lovaza...
Main Authors: | Scorletti, E, Bhatia, L, McCormick, K, Clough, G, Nash, K, Hodson, L, Moyses, H, Calder, P, Byrne, C |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2014
|
Similar Items
-
Potential benefits of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and Type 2 diabetes? Results from the WELCOME study
by: Scorletti, E, et al.
Published: (2014) -
Whole-body and hepatic dietary fatty acid oxidation is related to postprandial insulin concentrations in people with non-alcoholic fatty liver disease with varying degrees of insulin resistance
by: Hodson, L, et al.
Published: (2013) -
Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
by: Hodson, L, et al.
Published: (2017) -
Distinguishing Health Benefits of Eicosapentaenoic and Docosahexaenoic Acids
by: Fraser D. Russell, et al.
Published: (2012-11-01) -
Comparison and validation of a fast method for the extraction and quantification of α-linolenic, eicosapentaenoic, and docosahexaenoic fatty acids
by: Alejandro OVIEDO CASTRILLÓN, et al.
Published: (2016-12-01)